Acadian Asset Management LLC Fate Therapeutics Inc Transaction History

Acadian Asset Management LLC

$48.4 Billion
Q2 2025

A detailed history of Acadian Asset Management LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Acadian Asset Management LLC holds 2,459,954 shares of FATE stock, worth $2.26 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,459,954

Previous 2,473,565 0.55%

Holding current value

$2.26 Million

Previous $1.95 Million 41.09%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	SELL	$0.68 - $1.67 $9,255 - $22,730	-13,611 Reduced 0.55%	2,459,954 $2.75 Million
Q1 2025 May 21, 2025	BUY	$0.79 - $1.87 $789,820 - $1.87 Million	999,773 Added 67.84%	2,473,565 $1.95 Million
Q4 2024 Feb 11, 2025	SELL	$1.61 - $3.35 $206,608 - $429,898	-128,328 Reduced 8.01%	1,473,792 $2.43 Million
Q3 2024 Nov 12, 2024	SELL	$3.12 - $5.57 $1.27 Million - $2.27 Million	-406,742 Reduced 20.25%	1,602,120 $5.61 Million
Q2 2024 Aug 06, 2024	BUY	$3.26 - $7.08 $960,845 - $2.09 Million	294,738 Added 17.19%	2,008,862 $6.59 Million
Q1 2024 May 10, 2024	SELL	$3.54 - $8.35 $2.01 Million - $4.73 Million	-567,047 Reduced 24.86%	1,714,124 $12.6 Million
Q4 2023 Feb 13, 2024	BUY	$1.65 - $3.94 $217,097 - $518,401	131,574 Added 6.12%	2,281,171 $8.53 Million
Q3 2023 Nov 13, 2023	BUY	$2.02 - $5.04 $2.5 Million - $6.23 Million	1,236,680 Added 135.46%	2,149,597 $4.56 Million
Q2 2023 Aug 07, 2023	BUY	$4.76 - $6.59 $4.35 Million - $6.02 Million	912,917 New	912,917 $4.34 Million
Q2 2018 Jul 24, 2018	SELL	$9.16 - $13.48 $94,778 - $139,477	-10,347 Closed	0 $0
Q1 2018 Apr 12, 2018	BUY	$6.3 - $13.77 $65,186 - $142,478	10,347 New	10,347 $101,000

Others Institutions Holding FATE

# of Institutions

150

Shares Held

96.7M

Call Options Held

56.7K

Put Options Held

5.4K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $89.2M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.

Account

Acadian Asset Management LLC Fate Therapeutics Inc Transaction History